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Purpose: To develop a transdermal betahistine (BTH) delivery system using different pressure sensitive 
adhesives (PSAs) including acrylics, polyisobutylene and styrenic rubber solution. 
Methods: Formulations were prepared by solvent casting and adhesive transfer method. PSAs - 
acrylate vinylacetate (AVA), hydrophilic acrylate (HA), acrylic non-curing (ANC), polyisobutylene (PIB), 
and tackified styrenic rubber solution (TSR) - were evaluated for their suitability in terms of miscibility, 
maximum drug loading, effect on tack property and in vitro permeation through excised guinea pig skin. 
Furthermore, one of the PSAs was tested in relation to effect of penetration enhancers on tack property, 
in vitro permeation, in vivo patch adhesion performance and stability. 
Results: Only formulations prepared with AVA and HA were stable. Increased drug loading in these 
PSAs significantly reduced tack. In vitro permeation data across guinea pig skin demonstrated that BTH 
flux from from the formulation containing HA (F1) was significantly (p < 0.001) higher than that 
containing AVA (F2). Formulations containing 2 % enhancer showed good tack. Specifically, the 
formulation containing 2 % oleic acid as enhancer not only showed the highest permeation but also 
good tack property, non-irritancy for up to 36 h and stability under accelerated conditions. 
Conclusion:  The formulation containing HA as the PSA and 2 % oleic acid as enhancer demonstrated 
a good potential for further development to an adhesive-type transdermal delivery system for BTH.    
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INTRODUCTION 
 
Betahistine (BTH) is an orally active 
histamine analogue known to improve the 
microcirculation of labyrinth, resulting in 
reduced endolymphatic pressure, and is 
therefore, used in diseases characterised by 
impaired peripheral circulation (Meniere’s 
syndrome). Peroral administration exhibit 
extensive first-pass metabolism and gastric 
irritation in patients suffering from peptic 
ulcer. As the disease is mostly observed in 
elderly patients, frequent dosing due to short 
biological half life may lead to non-
compliance [1,2].  
 
Transdermal drug delivery (TDD) can 
overcome these problems and improve 
treatment protocols by maintaining plasma 
levels over the dosing interval. Amongst 
various approaches to formulation 
development, drug-in-adhesive represents 
the simplest formulation design whereby a 
pressure-sensitive adhesive (PSA) not only 
fulfils the adhesion-to-skin function but also 
serves as a formulation matrix incorporating 
the drug and all the excipients. Commonly 
used PSAs include polyisobutylenes (PIB), 
silicones, acrylics and styrenic rubber 
solution [3]. Since only a few drugs can be 
administered percutaneously due to their low 
permeability, the formulation strategy often 
involves incorporation of chemical 
permeation enhancers. Penetration 
enhancers generally act by partitioning into 
the skin and interacting with different skin 
constituents to elicit temporary and ideally 
reversible reduction of barrier properties. 
However, permeation rate, PSA compatibility 
and skin adhesion must be considered before 
selection of an enhancer [4,5]. 
 
In the present study, an attempt was made to 
develop an adhesive-type TDD system for 
BTH using five PSAs of varying 
functionalities. The effects of penetration 
enhancers on the tack and in vitro 
permeation of the formulations were also 
evaluated. The most suitable formulation was 
further assessed for in vivo patch adhesion 






Betahistine dihydrochloride was received as 
a gift from Geno Pharma, Goa, India. HPLC 
grade tetramethyl ammonium hydrogen 
sulphate and sodium heptane sulphonate 
(Merck Chemicals, Mumbai, India); HPLC 
grade methanol (Ranbaxy Fine Chemicals, 
New Delhi, India); N-methyl pyrrolidone 
(NMP), Isopropyl myristate (IPM), Dimethyl 
sulphoxide (DMSO), Dimethyl formamide 
(DMF) and Oleic acid (OA) – all from 
Lobachem, Mumbai, India - were purchased. 
Pressure-sensitive adhesives Duro Tak
®
 387-
2287A (a non-curing PSA containing 50.5 % 
acrylate-vinylacetate and with hydroxyl 
functionality, AVA), Duro Tak
®
 87-202A (a 
self-curing PSA containing 40 % hydrophilic 
acrylate and with hydroxyl functionality, HA), 
Duro Tak
®
 87-901A (an acrylic non-curing 
PSA containing 44 % solid content and 
without any functionality, ANC), Duro Tak
®
 
87-608A (polyisobutylene rubber solution 
containing 38 % solid content, PIB), and Duro 
Tak
®
 87-611A (tackified styrenic rubber 
solution containing 57.5 % solid content, 
TSR) were all received (as organic solvent 
solutions) as gifts from National Starch and 
Chemicals Ltd, USA. CoTran
®
 9720 
polyethylene backing film and Scotch pack
®
 
9741 SBOPP release liner were received as 
gifts from 3M, USA. All other chemicals were 
used as received, without further 
purification/treatment. 
 
Preparation of betahistine (BTH) base and 
selection of PSA 
 
BTH free base was liberated from its 
dihydrochloride salt by neutralization with 
strong sodium hydroxide solution followed by 
extraction with chloroform. The resultant 
extract was dried at room temperature to 
remove excess chloroform, leaving a viscous, 
dark yellow liquid [6]. Since selection of PSA 
matrix is a very important step in the design 
Heda et al 
Trop J Pharm Res, December 2010; 9(6): 518 
of adhesive-type TDD [4,7], it was necessary 
to select appropriate PSA by testing the 
miscibility of BTH with the PSAs under 
consideration (i.e., AVA, HA, ANC, PIB and 
TSR). Various formulations containing 
different ratios of BTH and PSAs were 
prepared and the resultant patches were 
subjected to microscopic examination. 
Miscibility was studied throughout the whole 
patch using a light microscope (Olympus 
camera SP-350, model CX 31, with Magnus 
PRO 3.0 image analysis software, 40 x 
magnification).  
 
BTH TDD was prepared by solvent evaporation 
method and fabricated by adhesive transfer 
technique. BTH (10 mg) was dissolved in 
sufficient quantity of chloroform and added to 
PSA solution. The proportion of BTH and PSA 
was varied (see Table 1 and 2) to obtain 
formulations F1 to F18. To formulations F19 to 
F28, various enhancers, namely, oleic acid 
(OA), isopropyl myristate (IPM), dimethyl 
sulphoxide (DMSO), dimethyl formamide (DMF) 
and N-methyl pyrrolidone (NMP) were added in 
different concentrations (see Table 3). The 
adhesive matrix was formed by casting the 
mixture on a release liner, using a casting knife 
to achieve the desired film thickness. It was set 
at room temperature for 20 min and 
subsequently oven-dried at 60 
0
C for 30 min to 
remove residual organic solvents. The dried film 
was then laminated onto a backing film using a 
standard 2 kg roller (Sri Sai Precision 
Instruments & R. C., Nasik, India) [8,9].  
 





Drug matrix composition 
             (mg:µL*) 
F1 10:125  (BTH : HA) 
F2 10:105  (BTH : AVA) 
F3 10:135  (BTH : PIB) 
F4 10:90  (BTH : TSR) 
F5 10:115  (BTH : ANC) 
F6 10:250 (BTH : HA) 
F7 10:200 (BTH : AVA) 
F8 10:270 (BTH : PIB) 
F9 10:180 (BTH : TSR) 
F10 10:230 (BTH : ANC) 
* The quantity of PSA solution was based on solid 
content. 
Table 2: Composition of formulations investigated 






F11 10:25  (BTH : HA) 
F12 10:50  (BTH : HA) 
F13 10:75  (BTH : HA) 
F14 10:100 (BTH : HA) 
F15 10:20(BTH : AVA) 
F16 10:40  (BTH : AVA) 
F17 10:60  (BTH : AVA) 
F18 10:80 (BTH : AVA) 
* The quantity of PSA solution was based on solid 
content. 
 
Evaluation of the effect of drug loading on 
tack properties and in vitro permeation 
 
Based on miscibility study, only adhesives 
with alcohol functionality (HA and AVA) were 
considered suitable for the preparation of the 
adhesive-type TDD system incorporating the 
drug. Since increase in drug loading is 
generally associated with increase in flux [4], 
further formulations containing higher BTH 
loading were prepared, as in Table 2. Tack 
parameter for all the formulations was 
subjectively evaluated by pressing a thumb 
briefly on the matrix [10]. Two formulations 
selected (F1 and F2), which showed 
adequate tack, were evaluated for in vitro 
permeation across guinea pig skin. 
Formulation F12 was also assessed to 
determine the effect of increase in drug 
loading on BTH permeation. 
 
 
In vitro skin permeation experiment 
 
The animal experiments were approved by 
Institutional Animal Ethics Committee (IAEC) 
of Government College of Pharmacy, 
Aurangabad, India (ref. no. GCPA/IAEC/ 
2008/330) and carried out as per the 
guidelines of the committee. Guinea pigs 
were housed in stainless steel cages and 
maintained under standard condition (12 h 
light/dark cycle; 25 
0
C, 45 % RH). The 
animals were fed normally with green leafy 
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vegetables and nutritional grains. They also 
freely received water and were acclimatized 
to laboratory conditions for one week before 
commencement of the experiment. The day 
before the experiment, hairs from the 
abdominal region of the guinea pigs were 
removed by a hair removing spray (Smooth 
skin, Regrace Ink, Mumbai). On the next day, 
full-thickness abdominal skin was excised 
and subcutaneous fats removed with scissors 
and scalpel. The excised skin was mounted 
on a modified Keshary Chien diffusion cell. 
Phosphate buffer (pH 7.4) was used as the 
receptor medium (15 ml, maintained at 32 ± 1 
0
C) and it was stirred continuously with a 
magnetic stirrer (Whirlmatic-Mega, Spectra-
lab). The transdermal patch (1 cm
2
) was 
applied to skin on the donor side of the 
diffusion cell. Aliquots of 1 ml were withdrawn 
from the receptor medium at sampling 
intervals of 1, 2, 3, 6, 12, 24, 48 h and sink 
condition was maintained by replenishing the 
medium with 1 ml of phosphate buffer. The 
withdrawn samples were centrifuged 
(Spinwin, Tarsons) for 10 min. at 1000 rpm 
[1] and
 
 analysed by high performance liquid 
chromatography (HPLC) as described below. 




BTH was assayed by an in-house developed 
and validated RP-HPLC method. The HPLC 
system (Dionex, Germering, Germany) 
consisting of Chromeleon 6.70 acquisition 
software equipped with P680 HPLC pump, 
ASI-100 automated sample injector and UVD 
170 UV detector. HPLC column Micra-NPS 
RP18 (length × OD × ID, 33 × 8.0 × 4.6 mm, 
1.5 µm), was used. Isocratic elution was 
performed using a mobile phase consisting of 
a pH 3.5 buffer (20 mM tetramethyl 
ammonium hydrogen sulphate and 9 mM 
sodium salt of heptane sulphonic acid) and 
methanol in a ratio of 97:3 with a flow rate of 
0.4 ml/min. A sample solution (05 µl) was 
injected into the column and analysed at a 
wavelength of 260 nm. 
 
Cumulative amounts of BTH (µg) permeated 
per unit area were plotted against time. Lag 
time (tL, h) was determined by extrapolating 
the linear portion of each curve to time axis. 
Steady state flux (Jss, µg/h/cm
2
) was 
calculated from the slope while permeability 
coefficient (Kp) was calculated using Eq 1.  
Cd
Jss
Kp =  ……………………… (1) 
where Cd denotes the concentration of BTH 
in the donor cell [11,12]. 
 
Evaluation of the effect of penetration 
enhancers on tack property and in vitro 
permeation  
 
Since formulation F1 provided the highest 
flux as well as optimum tack, it was 
necessary to further increase the permeation 
rate using suitable penetration enhancers. 
Five different enhancers, viz, NMP, IPM, 
DMSO, DMF or OA were added to F1 at 
concentrations of 2 and 4 %w/w (see Table 
3). The miscibility of enhancers with adhesive 
solution was tested by a previously reported 
method [13]. All the formulations were also 
evaluated by thumb tack test. The selected 
formulations (F19, F21, F23, F25 and F27) 
were then subjected to in vitro permeation 
study across guinea pig skin and 
enhancement ratio (ER) was calculated as 
the ratio between BTH flux from formulations 
with and without enhancers. 
 
In vivo patch adhesion performance test 
and stability studies 
 
Since in vitro conditions do not necessarily 
represent the performance of TDD systems 
under in vivo conditions, the adhesion 
performance of the developed formulations 
was tested in vivo on guinea pig skin [14]. 
Also, since the transdermal system was 
intended to be applied over a period of at 
least one day based on lag time 
considerations, 5 cm
2
 patch of F19 was 
applied to the guinea pig skin and observed 
every 12 h for 36 h. Patch adhesion 
performance to skin was scored from 0 to 4 
with 0 indicating that the patch was stuck 
Heda et al 
Trop J Pharm Res, December 2010; 9(6): 520 
firmly to the skin and 4 indicating that the 
patch completely peeled off the skin. 
Samples of F19 were wrapped in an 
aluminium foil, pouched in a self-sealing 
polybag and subjected to a 3-week 
accelerated stability condition by storing at 50 
0
C in an oven. Stability was evaluated in 
terms of tack and in vitro permeation profile. 
 
Table 3: Composition of formulations tested for 
the effect of penetration enhancers on tack 








10:125 (BTH : HA PSA)/2% v/v OA 
F20 10:125 (BTH : HA PSA)/4% v/v OA 
F21 10:125 (BTH : HA PSA)/2% v/v IPM 
F22 10:125 (BTH : HA PSA)/4% v/v IPM 
F23 10:125 (BTH : HAPSA)/2% v/v DMSO 
F24 10:125 (BTH : HA PSA)/4% v/v DMSO 
F25 10:125 (BTH : HA PSA)/2% v/v DMF 
F26 10:125 (BTH : HA PSA)/4% v/v DMF 
F27 10:125 (BTH : HA PSA)/2% v/v NMP 
F28 10:125 (BTH : HA PSA)/4% v/v NMP 
* The quantity of PSA solution was based on solid 
content; OA = oleic acid; IPM = isopropyl myristate; 
DMSO = dimethyl sulphoxide; DMF = dimethyl 




The data were analyzed using GraphPad 
InState Demo (version 3.10) and Microsoft 
Excel 2007. The permeation parameters 
obtained were compared by one-way 
analysis of variance (ANOVA). Tukey-Kramer 
test and Dunnett test were performed for 
multiple comparisons amongst the different 
formulations, respectively. The probability 





Selection of PSA matrix for development 
of drug-in-adhesive TDD  
 
Microscopic examination of F1, F2, F6, and 
F7 showed complete miscibility of BTH with 
two of the PSAs (HA and AVA). Prominent 
yellow-coloured spots in F3, F4, F5, F8, F9 
and F10 indicated immiscibility of BTH in 
ANC, PIB and TSR. 
 
Effect of drug loading on in vitro 
permeation and tack properties 
 
Maximum drug loading in HA and AVA was 
1:2 and 1:5, respectively. Increased drug 
loading in HA reduced tack significantly. 
Significant differences were observed 
between flux through F1, F2 and F12 
formulations (p < 0.001). F1 provided 
significantly higher flux (31.33 ± 0.90 
µg/h/cm
2
) than F2 (4.27 ± 1.05 µg/h/cm
2
). 
F12, containing high BTH loading, showed 
significantly higher flux (39.24 ± 1.02 
µg/h/cm
2
) than F1. However, significant loss 
of adhesion property was observed with 
increase in drug loading for F2 and F12. 
 
Effect of penetration enhancers on tack 
property and in vitro permeation 
 
All the five enhancers evaluated for miscibility 
dissolved homogenously in the adhesive 
solution. Thumb tack test data indicate that 
F20, F22, F24, F26, and F28 showed 
significant loss of adhesion property. Since 
these formulations (which contained high 
levels of enhancers) exhibited extremely poor 
tack, they were not considered suitable for 
the in vitro skin permeation studies. 
Formulations F19, F21, F23, F25 and F27 
exhibited good adhesion. Microscopic 
examination did not show any evidence of 
immiscibility, separation or oozing out of the 
enhancers. Their in vitro permeation data are 
shown in Table 4 while the cumulative 
amount of BTH permeated per unit area for 
these formulations are compared in Figure 1. 
F1 (without enhancer) served as control. F19 
containing OA as an enhancer exhibited the 
highest flux with an enhancement ratio 1.24 
which was significantly different from that of 
the control (F1, p < 0.01). F21 and F27 
containing 2 % IPM and NMP showed 
enhancement ratio of 1.06 and 0.97, 
respectively. This was not significantly 
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F1 (Control) 31.33 ± 0.90 18.40 ± 2.4 6.26 ± 0.16 +++ 1 
F19 38.88 ± 1.50
a
 9.66 ± 0.6
 a
 7.79 ± 0.35
a
 +++ 1.24 
F21 33.49 ± 2.38
b
 8.33 ± 1.1
a
 6.45 ± 0.92
b 
+++ 1.06 
F23 26.74 ± 3.23
a
 9.33 ± 0.5
a
 4.96 ± 0.16
a
 +++ 0.85 
F25 20.45 ± 3.57
a
 11.33 ± 0.5
a
 4.14 ± 0.14
a
 +++ 0.65 
F27 30.45 ± 0.44
b
 11.66 ± 0.4
a
 6.18 ± 0.28
b
 +++ 0.97 
+++ denotes good adhesion tested by thumb tack; ER = enhancement ratio. 
a
 Statistically significant different from the control (F1) (p < 0.01),  
b





Figure 1: Cumulative permeated BTH for 
transdermal formulations containing various 
permeation enhancers (Note: ■ = F19; ○ = F21; ● 
= F1; □ = F27; ♦ = F23; ▲= F25) 
 
different from that of the control. However, 
significant reduction in lag time was noted for 
F21 and F27 (p < 0.01). Enhancers DMSO 
and DMF (at a level of 2 %) produced 
significant reductions in flux, permeability 
coefficient and lag time compared with 
control (p < 0.01).  
 
In vivo patch adhesion and stability 
 
In the in vivo adhesion test on the most 
suitable formulation (F19), an estimated 90 % 
of the patch area remained adhered to the 
skin and was, therefore, scored 0 as it did not 
peel off the guinea pig skin for a period of 36 
h.  
 
Stability evaluation of F19 showed steady 
state flux of 37.3 ± 1.2 µg/cm
2
/h with a lag 
time of approx. 10 h. Statistically, no 
significant difference (p > 0.05) was observed 
between flux values before and after the 




PSA matrix, drug loading, permeation and 
tack properties 
 
A suitable PSA is necessary in the design of 
TDD to ensure adequate drug release and 
intimate contact of the transdermal patch with 
the skin. However, these polymeric 
adhesives exert their own effect on the 
solubility and permeability of the drug 
incorporated.  
 
The acrylic adhesives, HA and AVA (which 
have a hydroxyl functional group) showed 
complete miscibility with BTH which might be 
due to the chemical nature of these PSAs. 
The hydrophilic acrylic component of HA 
might have enhanced the solubility of BTH in 
line with the reported effect of HA on the 
solubility of hydrophilic drugs [15]. It has also 
been reported that the chemical nature of a 
transdermal adhesive can affect the solubility 
of the drug in the PSA matrix [16]. Jeans et al 
demonstrated that adhesives containing 
acidic side-chains are not compatible with the 
basic form of primaquine base; on the other 
hand, adhesives containing OH group 
produced homogenous and stable blends, 
possibly due to hydrogen bond formation with 
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primaquine base [9]. Similar observations 
were reported for granisetron base in that 
while adhesives comprising electronegative 
groups such as COOH groups could not be 
used to manufacture satisfactory transdermal 
patches of granisetron free base, an 
adhesive containing an OH functional group 
(Duro Tak
®
 387-2287A) was significantly 
better than non-nucleophilic, electroneutral 
adhesives [17].  
 
When tested for in vitro permeation, F1 
provided significantly higher flux than F2. 
Also, F12, which had high BTH loading, 
showed higher flux than F1; this supports the 
assumption that increase in drug loading 
increases drug permeation. Subsequently, 
however, there was a significant loss of 
adhesion by F12. Overall, drug loading, 
permeation and tack data suggest that HA 
was the most suitable PSA and was therefore 
employed for further evaluation. Furthermore, 
these results suggest that the chemical 
nature of PSA need to be considered before 
selecting an adhesive matrix (PSA). 
 
Effect of penetration enhancers on tack 
property and in vitro permeation  
 
To develop matrix-type transdermal delivery 
system for a drug, an appropriate vehicle is 
often required to enhance the permeation 
rate and/or to increase the solubility of the 
drug in the adhesive. A vehicle can also act 
as a plasticizer in the adhesive, increasing 
the mobility of the drug in the adhesive. To 
further increase the permeation rate of BTH 
and to reduce the lag time, the effect of some 
vehicles on the permeation of BTH from HA 
matrix was investigated. The amount of each 
vehicle tested was 2 and 4% of the weight of 
acrylic adhesive polymer, respectively. Since 
4% weight of permeation enhancer caused 
significant loss of adhesive force, the 
permeation rate was not determined for these 
formulations. 
 
Incorporation of OA into the acrylic adhesive 
matrix significantly enhanced permeation rate 
and shortened lag time. The enhancement 
effect of OA may be explained by the 
formation of permeable interfacial defects 
within the stratum corneum lipid bilayers 
which effectively decreased permeation 
resistance without necessarily invoking the 
formation of pores [18]. This might have 
increased the BTH permeation from HA 
matrix. The reported mechanism of 
permeation enhancement of IPM is by 
fluidization of intercellular lipids [19] whereas 
NMP rely on improving drug partitioning into 
the skin to promote permeation [20]. 
However, no such enhancing effects by these 
solvents were observed when tested for in 
vitro permeation of BTH across guinea pig 
skin. 
 
The permeation enhancement mechanism of 
sulphoxides and formamides (e.g., DMSO 
and DMF, respectively) is reported to be 
complex. They effectively promote 
permeation by reducing skin resistance to 
drug molecules or by promoting drug 
partitioning in the delivery system [22,22]. In 
the present work, DMSO and DMF also did 
not produce any significant increase in BTH 
permeation. Overall, 2 % OA proved to be the 
most effective and suitable penetration 
enhancer for HA - based transdermal BTH 
formulation since it resulted in the highest flux 
across the guinea pig skin while also showing 
the shortest lag time.  
 
In vivo patch adhesion and stability  
 
Several in vitro techniques, such as peel 
adhesion, tack and shear strength, have 
been used to monitor the adhesive 
performance of patches in vivo [23]. 
However, there is lack of evidence for a 
relationship between adhesion results 
obtained in vitro and those generated in vivo 
TDD systems [24]. F19 possessed adequate 
tack properties and remained adhered to skin 
for 36 h, a long enough period for TDD. The 
formulation was also stable for 3 weeks at 50 
0
C, an important requirement for adhesive 
systems 
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Previously reported bioavailability studies of 
BTH indicate that maximum plasma 
concentrations after oral dosings (50 mg/kg) 
to dogs were 2.6 - 4.8 ng/ml [1]. After a single 
dose of 24 mg betahistine mesylate to 20 
healthy Chinese male volunteers, the plasma 
concentration of the parent drug was less 
than 0.5 ng/ml [2]. Hence, the effective 
plasma concentration in man (oral dose 8-16 
mg once) would be at ng/ml level. Although 
the effective plasma concentration range of 
BTH in man has not been evaluated, the 
overall results of the present study suggest 





Acrylic acid-derived PSA containing hydroxyl 
functionality provided the most suitable matrix 
for BTH. The optimized formulation, F19, 
provided the highest flux with a lag time of 
approx 10 h. This patch showed adequate 
tack. These attributes warrants that further 
evaluation of this betahistine adhesive-type 
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